Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
IAEA Imagebank via Flickr CC
A federally appointed ethics panel has rejected a proposal to deliberately infect people with Zika virus, a common practice known as a human challenge study.
It was denied because there was "substantial uncertainty about the risks to potential volunteers," as well as potential risk to sexual partners, fetuses, and other members of the community. There are currently four experimental Zika vaccines in the earliest stages of human testing, according to STAT, but there is concern that the outbreak will be receding by the time vaccines are ready for testing in Phase 3 trials.
The unknowns: The panel cited how much has been discovered about Zika in the last six months alone about transmission and side effects as a reason to hold back right now. Anthony Fauci, director of the NIH's NIAID, told STAT he would likely approve a study on Zika infection side effects first.
What's ruffling feathers: The search for a vaccine is hampered with this decision, and any research group that wants to prove a vaccine works will want to conduct large human trials.